Form 4: ANI Pharmaceuticals Executive Christopher Mutz Reports Stock Transaction
SEC Form 4 Filing
Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals, reports a transaction involving the withholding of shares for tax purposes related to vesting restricted stock.
Summary
- On March 7, 2025, Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals, reported a transaction on SEC Form 4.
- The transaction involved the withholding of 2,874 shares of common stock at a price of $60.62 for tax purposes.
- This was related to the vesting of 6,476 shares of restricted stock previously reported.
- Following the transaction, Mutz directly owns 111,317 shares of ANI Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock transactions, and does not contain any information that would significantly impact sentiment.
Industry Context
This is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects an executive's stock ownership and compensation.
Key Dates
| Date | Description |
|---|---|
| 03/07/2025 | Date of stock transaction |
| 03/14/2025 | Date of signature on the report |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.